The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial
- Saglimbene, Valeria
- Palmer, Suetonia C.
- Ruospo, Marinella
- Natale, Patrizia
- Maione, Ausilia
- Nicolucci, Antonio
- Vecchio, Mariacristina
- Tognoni, Gianni
- Craig, Jonathan C.
- Pellegrini, Fabio
- Lucisano, Giuseppe
- Hegbrant, Joergen
- Ariano, Rosario
- Lamacchia, Olga
- Sasso, Antonio
- Morano, Susanna
- Filardi, Tiziana
- De Cosmo, Salvatore
- Pugliese, Giuseppe
- Procaccini, Deni A.
- Gesualdo, Loreto
- Palasciano, Giuseppe
- Johnson, David W.
- Tonelli, Marcello
- Strippoli, Giovanni F. M.
Publication date
December 2018
DOI Publisher
American Society of Nephrology (ASN)Abstract
Background The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.Methods In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting B
Add to ORKG